Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05909995 · ClinicalTrials.gov registry record · Phase 1
Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
A Phase 1 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT05909995 is a Phase 1 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 8 participants.
The verdict
NCT05909995, a Phase 1 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the safety, tolerability, PK, and efficacy of INCB 99280 in combination with ipilimumab in participants with select solid tumors.
Interventions
- DRUG INCB 99280 with Ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2023-08-29 |
| Est. Completion | 2024-11-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05909995
The ClinicalTrials.gov registry entry for NCT05909995 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which INCB 99280 with Ipilimumab is the first listed.
NCT05909995 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05909995 about?
NCT05909995 is a clinical study titled "Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors". The purpose of this study is to characterize the safety, tolerability, PK, and efficacy of INCB 99280 in combination with ipilimumab in participants with select solid tumors.
What is the current status of trial NCT05909995?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2023-08-29. Estimated completion is 2024-11-11.
What interventions are being tested in trial NCT05909995?
The interventions under investigation include: INCB 99280 with Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT05909995?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.